Melanoma used to have almost no effective treatment options. Now? Immunotherapy is changing lives — and Oxford’s Dr. Mark Middleton joins us to unpack the science, the turning points, and the innovations reshaping melanoma care.In this episode, he reflects on decades of research — from the early trials that taught researchers what not to do, to the breakthroughs in checkpoint inhibition and precision approaches that dramatically improved outcomes. We also dive into MyMelanoma, a nationwide effort gathering real-world patient data to answer questions traditional trials often leave behind.Takeaways:What researchers learned from early immunotherapy trial failures — and how those lessons shaped today’s strategies The evolving science behind checkpoint inhibitors and why certain patients respond more durably than othersHow MyMelanoma is uncovering insights on risk, survivorship, lifestyle factors, and real-world outcomes at scale The future of melanoma treatment, including biomarkers, combinatorial approaches, and better trial designs

Ver todos los episodios